Related Experiment Videos
Prevention or reversal of atherosclerosis: review of current evidence
1Department of Medicine, University of Southern California School of Medicine, Los Angeles 90033.
Insights
Lipid-reducing agents help stabilize and regress coronary atherosclerotic lesions, lowering heart disease risks. Studies show these treatments reduce morbidity and mortality from coronary heart disease.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Coronary heart disease (CHD) poses significant morbidity and mortality risks.
- Lipid-lowering therapies are crucial for managing cardiovascular health.
Purpose of the Study:
- To summarize the effects of lipid-reducing agents on coronary atherosclerotic lesions.
- To highlight the association between lipid reduction and cardiovascular outcomes.
Main Methods:
- Review of morbidity and mortality studies (cholestyramine, gemfibrozil, niacin).
- Analysis of angiographic studies on lipid-reducing agents and diet counseling.
Main Results:
- Lipid-reducing agents stabilize, slow progression, and can regress atherosclerotic lesions.
- Reduced lipid levels correlate with decreased CHD mortality.
- Niacin demonstrates long-term cardiovascular mortality reduction.
Conclusions:
- Lipid-reducing therapies offer benefits at the atherosclerotic lesion level.
- Effective management of lipid levels is key to reducing cardiovascular events.
Abstract:
Treatment with lipid-reducing agents is associated with reduced morbidity and mortality from coronary heart disease. Such treatment appears to work at the level of the atherosclerotic lesion, causing stabilization, slowed progression and, in some cases, regression of lesions. Morbidity and mortality studies of cholestyramine and gemfibrozil treatment have shown that a reduction of lipid levels was associated with reduced mortality from coronary heart disease; niacin treatment has been shown to have long-term effects on reducing cardiovascular mortality. Angiographic studies have documented that beneficial effects of treatment with lipid-reducing agents and intensive computer-assisted diet counseling occur at the level of the coronary atherosclerotic lesion.